Application of clostridium praeparatum CCFM1204 in preparation of medicine for prolonging service life, resisting oxidation, reducing fat and reducing lipofuscin deposition

CN119015326APending Publication Date: 2024-11-26JIANGNAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411365540.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-29
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

现有技术并未提及普拉梭菌在延长寿命方面的影响,也没有证据证明普拉梭菌具有延长寿命的功效

Benefits of technology

[0060] The present invention confirms that Faecalibacterium prausnitzii CCFM1204 has the effects of extending lifespan, resisting oxidation, reducing fat, and reducing lipofuscin deposition, which are specifically reflected in:

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015326A_ABST
    Figure CN119015326A_ABST
Patent Text Reader

Abstract

The invention discloses application of clostridium praeparatum CCFM1204 in preparation of drugs for prolonging life, resisting oxidation, reducing fat and reducing lipofuscin deposition, and belongs to the technical field of biology. The clostridium praeparatum CCFM1204 is recorded in a patent application file with the publication number of CN115074276B. The clostridium praeparatum CCFM1204 is proved to have excellent effects of prolonging the service life, reducing ROS and superoxide anion levels, reducing lipid deposition and reducing lipofuscin deposition, so that related products can be effectively developed based on the clostridium praeparatum CCFM1204, and the clostridium praeparatum CCFM1204 has wide application prospects and popularization values.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention specifically relates to the application of Faecalibacterium prausnitzii CCFM1204 in the preparation of medicines for prolonging life, resisting oxidation, reducing fat and reducing lipofuscin deposition, and belongs to the field of biotechnology. Background Art

[0002] As society's demand for longer healthy life expectancy increases, research and development of drugs related to life extension becomes particularly important. Extending life expectancy is not only related to the health and well-being of individuals, but also has a profound impact on the socio-economic and medical resource allocation. As the global population ages, extending healthy life expectancy can reduce the burden of age-related diseases, improve the quality of life of the elderly, and may also reduce the pressure on the social medical system.

[0003] In recent years, with the deepening of microbiome research, people have become increasingly aware of the important role of intestinal microbiota in health and disease. Studies have shown that with age, the composition and diversity of intestinal microbiota may change, and this change is related to processes such as oxidative stress and lipid deposition. Therefore, regulating the intestinal microbiota by supplementing probiotics may help prolong life. There is prior art that shows that there may be a connection between Faecalibacterium prausnitzii and anti-aging: for example, the Chinese invention patent application with publication number CN117119907A mentions that Faecalibacterium prausnitzii has anti-aging effects, but the invention content mainly enhances the growth of Faecalibacterium prausnitzii by using inositol, erythritol or sorbitol, and lacks direct data to prove that Faecalibacterium prausnitzii has anti-aging effects; the U.S. patent application with publication number US20230172999A1 discloses the use of a probiotic complex based on Faecalibacterium prausnitzii for alleviating weakness and inflammation caused by aging, mainly emphasizing the anti-inflammatory effects of 7 probiotic complexes, resulting in unclear effects of Faecalibacterium prausnitzii alone.

[0004] Although existing technologies indicate that there may be a certain connection between Faecalibacterium prausnitzii and anti-aging, it should be made clear that anti-aging is not equivalent to prolonging life. Aging is a slow, systemic, multifaceted, very complex, and gradual degeneration process that occurs in an organism in the later stages of its life. This degeneration process leads to a gradual decline in the body's adaptability and reserve capacity, which is specifically manifested in the decline or loss of function of various systems, organs, and tissues. Anti-aging refers to an active health care system that focuses on delaying the aging process of cells and tissues based on an understanding of the aging mechanism, adopts various programs, health products, and drugs to maintain a youthful state of body function and appearance, reduce the risk of age-related chronic diseases, and delay the aging process. Lifespan refers to the time from birth to death, and the measure of lifespan is age. The length of lifespan depends on innate genetic factors and acquired environmental factors.

[0005] Therefore, the development of life extension drugs is different from anti-aging. Life extension drugs are more directly focused on increasing the maximum lifespan of an organism, that is, extending the total time from birth to death of an organism, which usually involves gene regulation, cell signaling pathways, and adjustment of environmental factors. In short, anti-aging focuses on delaying the aging process and maintaining a healthy state, while life extension focuses more on actually increasing the length of an individual's life cycle. The prior art does not mention the effect of Faecalibacterium prausnitzii on prolonging lifespan, nor is there any evidence that Faecalibacterium prausnitzii has the effect of prolonging lifespan.

[0006] In summary, the use of probiotics to prepare drugs related to prolonging life is of great significance in meeting the challenges of an aging population, improving the quality of life, and preventing diseases. The development of these drugs not only helps to meet people's pursuit of health and longevity, but also provides new ideas and methods for medical research and clinical practice. Summary of the invention

[0007] Faecalibacterium prausnitzii is a Gram-negative bacterium belonging to the genus Faecalibacterium. It is very abundant in the human intestine and plays an important role in the intestinal microbial community of healthy individuals. In order to solve the deficiencies of the prior art, the purpose of the present invention is to provide a strain of Faecalibacterium prausnitzii CCFM1204 for use in prolonging life, anti-oxidation, reducing fat, and reducing lipofuscin deposition.

[0008] The first object of the present invention is to provide the use of Faecalibacterium prausnitzii CCFM1204 or its microbial agent in the preparation of a product with a prolonged lifespan.

[0009] In one embodiment of the present invention, the prolonging lifespan refers to increasing the number of days that Caenorhabditis elegans survives.

[0010] In one embodiment of the present invention, the Faecalibacterium prausnitzii CCFM1204 is recorded in the patent application document with publication number CN115074276B, and the deposit number is GDMCC No: 62239.

[0011] In one embodiment of the present invention, the microbial agent uses Faecalibacterium prausnitzii CCFM1204 as the main microorganism.

[0012] In one embodiment of the present invention, the number of viable bacteria of Faecalibacterium prausnitzii CCFM1204 in the bacterial agent is not less than 1×10 8 CFU / mL or 1×10 8 CFU / g.

[0013] In one embodiment of the present invention, the bacterial agent is obtained by preparing the seed solution of Faecalibacterium prausnitzii CCFM1204 and then expanding the culture.

[0014] In one embodiment of the present invention, the microbial agent contains living cells of the CCFM1204 strain of the present invention, dry cells of the CCFM1204 strain obtained by freeze-drying, immobilized cells of the CCFM1204 strain, liquid agent of the CCFM1204 strain, solid agent of the CCFM1204 strain, or the CCFM1204 strain in any other form.

[0015] In one embodiment of the present invention, the bacterial agent further contains other applicable strains of any species, including but not limited to Bacillus licheniformis, Saccharomyces cerevisiae, Bacillus subtilis, and Lactobacillus.

[0016] In one embodiment of the present invention, the product includes but is not limited to medicines, foods, food additives, feeds, feed additives, cosmetics, and health products.

[0017] In one embodiment of the present invention, the drug contains the above-mentioned Faecalibacterium prausnitzii CCFM1204 or its bacterial agent, and pharmaceutically acceptable excipients.

[0018] In one embodiment of the present invention, the auxiliary materials include any one of carriers, diluents, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, antibacterial agents or buffers, or a combination of at least two of them.

[0019] In one embodiment of the present invention, the carrier includes but is not limited to liposomes and nanoparticles.

[0020] In one embodiment of the present invention, the excipient is one or more of mannitol, lactose, fatty acid, and polyethylene glycol.

[0021] In one embodiment of the present invention, the dosage form of the drug includes any one of suspension, granules, capsules, powders, tablets, emulsions, solutions, pills, injections, suppositories, enemas, aerosols, patches or drops.

[0022] In one embodiment of the present invention, the administration route of the drug includes oral administration, sublingual administration, skin mucosal administration, inhalation administration or injection administration.

[0023] In one embodiment of the present invention, the food is solid food, liquid food or semi-solid food.

[0024] In one embodiment of the present invention, the content of Faecalibacterium prausnitzii CCFM1204 in the product is not less than 1×10 8 CFU / g or 1×10 8 CFU / mL.

[0025] In one embodiment of the present invention, the product has at least the function of extending the life, and may also have one or more of the following functions (a) to (c):

[0026] (a) Antioxidant;

[0027] (b) fat loss;

[0028] (c) Reduce lipofuscin deposition.

[0029] The second object of the present invention is to provide the use of Faecalibacterium prausnitzii CCFM1204 or its microbial agent in the preparation of products having the effects of prolonging life, anti-oxidation, reducing fat and reducing lipofuscin deposition.

[0030] In one embodiment of the present invention, the prolonging lifespan refers to increasing the number of days that Caenorhabditis elegans survives.

[0031] In one embodiment of the present invention, the Faecalibacterium prausnitzii CCFM1204 is recorded in the patent application document with publication number CN115074276B, and the deposit number is GDMCC No: 62239.

[0032] In one embodiment of the present invention, the microbial agent uses Faecalibacterium prausnitzii CCFM1204 as the main microorganism.

[0033] In one embodiment of the present invention, the number of viable bacteria of Faecalibacterium prausnitzii CCFM1204 in the bacterial agent is not less than 1×10 8 CFU / mL or 1×10 8 CFU / g.

[0034] In one embodiment of the present invention, the bacterial agent is obtained by preparing the seed solution of Faecalibacterium prausnitzii CCFM1204 and then expanding the culture.

[0035] In one embodiment of the present invention, the microbial agent contains living cells of the CCFM1204 strain of the present invention, dry cells of the CCFM1204 strain obtained by freeze-drying, immobilized cells of the CCFM1204 strain, liquid agent of the CCFM1204 strain, solid agent of the CCFM1204 strain, or the CCFM1204 strain in any other form.

[0036] In one embodiment of the present invention, the bacterial agent further contains other applicable strains of any species, including but not limited to Bacillus licheniformis, Saccharomyces cerevisiae, Bacillus subtilis, and Lactobacillus.

[0037] In one embodiment of the present invention, the product includes but is not limited to medicines, foods, food additives, feeds, feed additives, cosmetics, and health products.

[0038] In one embodiment of the present invention, the drug contains the above-mentioned Faecalibacterium prausnitzii CCFM1204 or its bacterial agent, and pharmaceutically acceptable excipients.

[0039] In one embodiment of the present invention, the auxiliary materials include any one of carriers, diluents, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, antibacterial agents or buffers, or a combination of at least two of them.

[0040] In one embodiment of the present invention, the carrier includes but is not limited to liposomes and nanoparticles.

[0041] In one embodiment of the present invention, the excipient is one or more of mannitol, lactose, fatty acid, and polyethylene glycol.

[0042] In one embodiment of the present invention, the dosage form of the drug includes any one of suspension, granules, capsules, powders, tablets, emulsions, solutions, pills, injections, suppositories, enemas, aerosols, patches or drops.

[0043] In one embodiment of the present invention, the administration route of the drug includes oral administration, sublingual administration, skin mucosal administration, inhalation administration or injection administration.

[0044] In one embodiment of the present invention, the food is solid food, liquid food or semi-solid food.

[0045] In one embodiment of the present invention, the content of Faecalibacterium prausnitzii CCFM1204 in the product is not less than 1×10 8 CFU / g or 1×10 8 CFU / mL.

[0046] The third object of the present invention is to provide a drug with the function of prolonging life, wherein the drug contains the above-mentioned Faecalibacterium prausnitzii CCFM1204 or its microbial agent, and pharmaceutically acceptable excipients.

[0047] In one embodiment of the present invention, the bacterial agent contains living cells of the CCFM1204 strain of the present invention, dry bacteria of the CCFM1204 strain obtained by freeze-drying, immobilized cells of the CCFM1204 strain, liquid bacterial agent of the CCFM1204 strain, solid bacterial agent of the CCFM1204 strain, or the CCFM1204 strain in any other form.

[0048] In one embodiment of the present invention, the auxiliary materials include any one of carriers, diluents, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, antibacterial agents or buffers, or a combination of at least two of them.

[0049] In one embodiment of the present invention, the carrier includes but is not limited to liposomes and nanoparticles.

[0050] In one embodiment of the present invention, the excipient is one or more of mannitol, lactose, fatty acid, and polyethylene glycol.

[0051] In one embodiment of the present invention, the dosage form of the drug includes any one of suspension, granules, capsules, powders, tablets, emulsions, solutions, pills, injections, suppositories, enemas, aerosols, patches or drops.

[0052] In one embodiment of the present invention, the administration route of the drug includes oral administration, sublingual administration, skin mucosal administration, inhalation administration or injection administration.

[0053] In one embodiment of the present invention, the medicine further contains strains of any genus that can be used in medicine, including but not limited to Bacillus licheniformis, Saccharomyces cerevisiae, Bacillus subtilis, and Lactobacillus.

[0054] In one embodiment of the present invention, the number of viable bacteria of Faecalibacterium prausnitzii CCFM1204 in the drug is not less than 1×10 8 CFU / mL or 1×10 8 CFU / g.

[0055] In one embodiment of the present invention, the drug at least has the function of prolonging life, and may also have one or more of the following functions (a) to (c):

[0056] (a) Antioxidant;

[0057] (b) fat loss;

[0058] (c) Reduce lipofuscin deposition.

[0059] Beneficial effects:

[0060] The present invention confirms that Faecalibacterium prausnitzii CCFM1204 has the effects of prolonging life, anti-oxidation, reducing fat, and reducing lipofuscin deposition, which is specifically embodied in:

[0061] (1) Lifespan experiments confirmed that Clostridium prausnitzii CCFM1204 can significantly extend the lifespan of C. elegans;

[0062] (2) By detecting ROS and superoxide anions (O2 - ) levels confirmed that Clostridium prausnitzii CCFM1204 could reduce ROS and superoxide anion (O2 - ) level, exerting antioxidant effect;

[0063] (3) Nile red staining experiments confirmed that F. prausnitzii CCFM1204 could reduce lipid deposition;

[0064] (4) Lipofuscin analysis experiments confirmed that Faecalibacterium prausnitzii CCFM1204 could significantly reduce lipofuscin deposition in Caenorhabditis elegans.

[0065] Therefore, Faecalibacterium prausnitzii CCFM1204 has broad application prospects and promotion value in the preparation of drugs for prolonging life, anti-oxidation, reducing fat, and reducing lipofuscin deposition. BRIEF DESCRIPTION OF THE DRAWINGS

[0066] Figure 1 This is a diagram showing the effect of Clostridium prausnitzii CCFM1204 on the lifespan of Caenorhabditis elegans.

[0067] Figure 2 Effects of Clostridium prausnitzii CCFM1204 on ROS and O2 in Caenorhabditis elegans - Representative plots of horizontal effects.

[0068] Figure 3 This is a quantitative analysis of the effect of Clostridium prausnitzii CCFM1204 on ROS levels in Caenorhabditis elegans.

[0069] Figure 4 The effect of Clostridium prausnitzii CCFM1204 on superoxide anion (O2 - ) level quantitative analysis chart.

[0070] Figure 5 Representative images of the effects of Faecalibacterium prausnitzii CCFM1204 on lipid deposition in Caenorhabditis elegans.

[0071] Figure 6This is a quantitative analysis of the lipid deposition of Caenorhabditis elegans by Clostridium prausnitzii CCFM1204.

[0072] Figure 7 Representative graphs showing the effects of Faecalibacterium prausnitzii CCFM1204 on lipofuscin deposition in Caenorhabditis elegans.

[0073] Figure 8 This is a quantitative analysis of the deposition of lipofuscin in Caenorhabditis elegans by Clostridium prausnitzii CCFM1204. DETAILED DESCRIPTION

[0074] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0075] The following examples are provided for a better understanding of the present invention, but are not intended to limit the present invention. The experimental methods in the following examples are conventional methods unless otherwise specified. The test materials used in the following examples are purchased from conventional biochemical reagent stores unless otherwise specified. The quantitative tests in the following examples were repeated three times, and the results were averaged.

[0076] The reagents and materials involved in the following examples are as follows:

[0077] Cholesterol (item number: 69008216), anhydrous ethanol (item number: 40021279), sodium hypochlorite (item number: 40021279), sodium chloride (item number: 10019360), agar powder (item number: 10000582), tryptone (item number: 69024138), anhydrous disodium hydrogen phosphate (item number: XW755879402), anhydrous potassium dihydrogen phosphate (item number: 100176193), anhydrous potassium hydrogen phosphate (item number: 1042920), anhydrous magnesium sulfate (item number: T40864 ), anhydrous calcium chloride (catalog number: 53219961), yeast powder (catalog number: 5501460B), sodium hydroxide (catalog number: G19852BYd), glucose (catalog number: T0887), cellobiose (catalog number: 63001434), fructose (catalog number: T2954), cysteine ​​(catalog number: 62007534), sodium bicarbonate (catalog number: 100189603), ammonium sulfate (catalog number: 1000291933), levamisole (catalog number: L0438) were purchased from Sinopharm Chemical Reagent Co., Ltd.;

[0078] Clarified rumen fluid (catalog number: A386) was purchased from Shanghai Chuangsai Technology Co., Ltd.;

[0079] DCFH-DA (Cat. No.: S0033S), DHE (Cat. No.: S0063), and lipid droplet red fluorescence detection kit (Cat. No.: C2051S) were purchased from Biotechnologies;

[0080] N2 wild-type Caenorhabditis elegans was provided by CGC American Caenorhabditis elegans Center (University of Minnesota, MN, USA).

[0081] The preservation number of Faecalibacterium prausnitzii CCFM1204 is GDMCC No: 62239, which was recorded in the patent application document with publication number CN115074276B on June 24, 2022.

[0082] The solutions involved in the following examples are as follows:

[0083] Stock solution preparation: 1M phosphate buffer (35.6g K2HPO4, 108.3g KH2PO4, pH 6.0, constant volume 1L); 1M CaCl2 solution; 1M MgSO4 solution; 5mg / mL cholesterol solution (prepared with anhydrous ethanol).

[0084] M9 buffer: 3g KH2PO4, 6g Na2HPO4, 5g NaCl and 1mL 1M MgSO4 solution, 1L deionized water, mix well, and autoclave at 121℃ for 20min.

[0085] Lysis solution: NaClO 5mL (5%), NaOH (10mol / L) 1.25mL, and sterile water 18.75mL, prepared for use immediately.

[0086] Nematode anesthetic levamisole: 1 M levamisole was prepared using M9 buffer for in vivo observation of nematodes.

[0087] Agarose pad: Prepare 2% agarose solution, heat and melt it, then take 800 μL and pour it into a small square grid made of six slides (two overlapping slides on each side and two cross slides in the middle). Use it as soon as possible after the agar solidifies.

[0088] The culture medium involved in the following examples is as follows:

[0089] M2GSC solid culture medium (1L): 10g tryptone, 5g yeast extract, 5g glucose, 2g cellobiose, 2g fructose, 1g cysteine, 4g sodium bicarbonate, 0.45g dipotassium hydrogen phosphate, 0.45g potassium dihydrogen phosphate, 0.9g ammonium sulfate, 0.9g sodium chloride, 0.09g calcium chloride, 0.09g magnesium sulfate heptahydrate, 10mL clarified rumen fluid (for physiological characteristics detection), 15g agar, pH adjusted to 6.5-6.8, and autoclaved at 115°C for 20min.

[0090] M2GSC liquid culture medium (1L): 10g tryptone, 5g yeast extract, 5g glucose, 2g cellobiose, 2g fructose, 1g cysteine, 4g sodium bicarbonate, 0.45g dipotassium hydrogen phosphate, 0.45g potassium dihydrogen phosphate, 0.9g ammonium sulfate, 0.9g sodium chloride, 0.09g calcium chloride, 0.09g magnesium sulfate heptahydrate, 10mL clarified rumen fluid (for physiological characteristics detection), pH adjusted to 6.5-6.8, and autoclaved at 115°C for 20min.

[0091] LB liquid culture medium: 10 g tryptone, 5 g yeast powder, 10 g NaCl, add deionized water to 1 L, adjust the pH to 7.0, and sterilize at 121°C for 20 min.

[0092] NGM medium preparation (1L): 3g NaCl, 2.5g peptone, 20g agar, 25mL 1M phosphate buffer, 1mL 1M CaCl2 solution, 1mL 1M MgSO4 solution, 973mL H2O. Autoclave at 121℃ for 20min. Cool to room temperature, add 1mL 5mg / mL cholesterol solution, mix well, and add to the culture dish.

[0093] The experimental methods involved in the following examples are as follows:

[0094] 1. Preparation of bacterial suspension:

[0095] (1) Strain activation: Take a Faecalibacterium prausnitzii CCFM1204 glycerol storage tube, inoculate it in M2GSC liquid medium, and culture it in an anaerobic workstation at 37°C for 18 hours to activate the strain. Take a Escherichia coli OP50 glycerol storage tube and inoculate it in LB liquid medium and culture it in a shaking incubator at 37°C (180 rpm) for 18 hours.

[0096] (2) Strain subculture: Take the activated culture fluid of Faecalibacterium prausnitzii CCFM1204 strain and inoculate it into new M2GSC liquid medium at an inoculum volume of 2% (v / v), and culture it in an anaerobic workstation at 37°C for 18 hours. Repeat this step to subculture the strain three times, and repeat this step to expand the culture. The activated culture fluid of Escherichia coli OP50 is inoculated into LB liquid medium in the same manner as above, and expanded in a shaking incubator (180 rpm) at 37°C.

[0097] (3) Calculation of viable bacteria: CCFM1204 and OP50 bacterial solutions were diluted to 10% by the plate counting method. 5 , 10 6 and 10 7 Times, take the diluted CCFM1204 bacterial solution and OP50 bacterial solution and spread them on the surface of M2GSC solid culture medium and LB liquid culture medium respectively, and count them after 48h of cultivation.

[0098] (4) Preparation of bacterial suspension: The number of live bacteria was 1×10 8 The CCFM1204 and OP50 bacterial suspensions with CFU / mL were centrifuged at 5000 rpm for 5 min to remove the culture medium, then washed with sterile water and centrifuged (5000 rpm for 5 min) to obtain bacterial precipitates, which were then resuspended with sterile water to prepare CCFM1204 and OP50 bacterial suspensions.

[0099] 2. Preparation of nematodes:

[0100] (1) Nematode culture

[0101] The present invention introduces N2 wild-type Caenorhabditis elegans into a culture medium containing 1×10 8 The cells were cultured in NGM culture dishes with OP50 bacterial suspensions of 10.3 CFU / mL and maintained and tested in a constant temperature incubator at 20°C using standard methods.

[0102] (2) Nematode passaging

[0103] Under laboratory conditions, nematodes reproduce quickly. To prevent the nematodes from starving and affecting the experiment, subculture inoculation is required. Use a razor blade to cut the old culture medium containing nematodes into a suitable size and transfer it to a new NGM culture dish.

[0104] (3) Synchronization of nematodes

[0105] When there are enough eggs and reproductive nematodes on the NGM culture dish, rinse them with M9 buffer into a 15mL centrifuge tube, repeat the wash twice, discard the supernatant and transfer to a 1.5mL centrifuge tube, add 1mL of lysis buffer, rotate on a rotary mixer for 10min, centrifuge at 5000×g for 1min, wash three times with M9 buffer, add M9 buffer and culture in a 20℃ incubator overnight. When the eggs hatch, you can obtain L1 larvae of the same period.

[0106] Example 1: Application of Faecalibacterium prausnitzii CCFM1204 in the preparation of drugs for prolonging life, anti-oxidation, reducing fat, and reducing lipofuscin deposition

[0107] 1. To detect the effects of Faecalibacterium prausnitzii CCFM1204 on the lifespan, antioxidant capacity, lipid and lipofuscin deposition of Caenorhabditis elegans.

[0108] The specific experiments are as follows:

[0109] CCFM1204 bacterial suspension, OP50 bacterial suspension, and L1 larvae were taken to test the effect of CCFM1204 on nematodes. The steps are as follows:

[0110] The bacterial concentration was 1×10 8 CFU / mL of CCFM1204 bacterial suspension, bacterial concentration of 1×10 8 CFU / mL of OP50 bacterial suspension was spread on a 60 mm NGM culture dish, and an equal number of synchronized L1-stage nematodes were transferred to the NGM culture dishes containing the CCFM1204 bacterial suspension or OP50 bacterial suspension, which were respectively the CCFM1204 group and the control group, and cultured in a constant temperature incubator at 20°C until the nematodes died.

[0111] 2. Experimental results

[0112] Count the survival rate of nematodes and detect ROS and O2 in nematodes - , lipid, lipofuscin indicators:

[0113] (1) Analysis of nematode lifespan

[0114] Unless otherwise specified, all experiments used the L4 period (day 3) as t=0. 150 nematodes were tested in 5 culture dishes for each group (30 / dish). The survival of nematodes was tested and recorded every day. The nematodes were transferred to a fresh culture dish every 2 days until all nematodes died. Nematodes were judged dead when pharyngeal suction stopped or there was no response to the gentle mechanical stimulation of the platinum wire of the worm picker. Nematodes that were accidentally lost, killed by internal hatching, damaged by squeezing organs, or injured during transfer were not counted in the lifespan statistics.

[0115] The mean lifespan (MLS, days) was calculated using the following formula:

[0116]

[0117] Among them, d j In this time period (x j , x j+1 ) is the number of dead nematodes, and N is the total number of dead nematodes. The standard error of the mean lifespan (SEM) was estimated using the following formula:

[0118]

[0119] The lifespan survival curve is Figure 1 shown.

[0120] The results showed that compared with the control group (average lifespan was 14.86±0.39 days, and the longest lifespan was 26 days), the intervention with Faecalibacterium prausnitzii CCFM1204 significantly prolonged the lifespan of nematodes (P<0.0001), with an average lifespan of 18.37±0.67 days and a longest lifespan of 30 days. After the intervention with Faecalibacterium prausnitzii CCFM1204, the average lifespan of nematodes increased by 23.4% compared with the control group.

[0121] (2) Nematode ROS and O2 - Determination

[0122] 2,7-dichlorofluorescein diacetate (DCFH-DA) and dihydroethylammonium (DHE) probes were used to measure ROS and O2 in nematodes, respectively. - level.

[0123] The two groups of C. elegans cultured to the 7th day were washed 2-3 times and incubated with 10μM DCFH-DA and 10μM DHE probes at 37°C in the dark for 60 minutes. After the dye was fully washed off with M9 buffer, the C. elegans were aspirated onto a glass slide and anesthetized with 25mM levamisole. Fluorescence imaging was performed using a laser confocal scanning microscope (Olympus FV1200, Japan) at excitation light (488-519nm) and (488-518nm), respectively. Fluorescence quantification was performed using Image J (National Institutes of Health, Bethesda, MD, USA). Twenty C. elegans were observed in each group, and three parallel experiments were performed.

[0124] ROS and O2 in Caenorhabditis elegans - Representative images and quantitative analysis results are shown in Figure 2 to Figure 4 shown.

[0125] The results showed that after 7 days of CCFM1204 intervention with Clostridium prausnitzii, the average fluorescence intensity of ROS in the control group was 54.12, while that in the CCFM1204 group was 39.61, a decrease of 26.8%. - The average fluorescence intensity was 26.57, and the average fluorescence intensity of the CCFM1204 group was 18.42, and the fluorescence intensity decreased by 30.6%, that is, the ROS and O2 - The fluorescence intensity was significantly lower than that of the control group (P<0.0001).

[0126] It can be seen that Faecalibacterium prausnitzii CCFM1204 can significantly improve the antioxidant level of nematodes.

[0127] (3) Determination of nematode lipids

[0128] The lipid droplet red fluorescence detection kit (fluorescent probe Nile Red) was used to measure the lipid level in nematodes. The two groups of C. elegans cultured to the 7th day were washed 2-3 times and incubated in the dark at 37°C for 60 minutes using the Nile Red probe. After the dye was fully washed off with M9 buffer, the C. elegans was aspirated onto a slide and anesthetized with 25mM levamisole. Fluorescence imaging was performed using a laser confocal scanning microscope under excitation light (552-636nm), and fluorescence quantification was performed using Image J. Twenty C. elegans were observed in each group, and three parallel experiments were performed.

[0129] Representative images of C. elegans Nile red staining and quantitative analysis results are shown in Figure 5 and Figure 6 shown.

[0130] The results showed that after 7 days of intervention with Faecalibacterium prausnitzii CCFM1204, the average fluorescence intensity of the control group was 63.89, and the average fluorescence intensity of the CCFM1204 group was 35.7, a decrease of 44.12%. Faecalibacterium prausnitzii CCFM1204 can significantly reduce lipid deposition (P < 0.0001).

[0131] (4) Analysis of lipofuscin in nematodes

[0132] In C. elegans, intestinal autofluorescence (called lipofuscin or "age pigment") accumulates with age and is often used as a marker of health or rate of aging.

[0133] The test nematodes (cultured to the 4th, 8th, and 12th days) were washed three times with M9 buffer, and then fixed on a 2% agarose pad with 25 mM levamisole, and fluorescence imaging was performed using a laser confocal scanning microscope with blue excitation light (405-488 nm) and DAPI. Image J software was used to analyze the accumulation level of lipofuscin in 4-, 8-, and 12-antenna nematodes.

[0134] Representative images and quantitative analysis of lipofuscin Figure 7 and Figure 8 shown.

[0135] The results showed that lipofuscin increased with age in both groups of nematodes;

[0136] On the 4th day, the average fluorescence intensity of the control group was 30.64, and the average fluorescence intensity of the CCFM1204 group was 24.73, with a decrease of 19.28%;

[0137] On the 8th day, the average fluorescence intensity of the control group was 75.25, and the average fluorescence intensity of the CCFM1204 group was 70.87, with a decrease of 5.82%;

[0138] On the 12th day, the average fluorescence intensity of the control group was 92.05, and the average fluorescence intensity of the CCFM1204 group was 62.63, with a decrease of 31.96%.

[0139] Statistical analysis showed that the lipofuscin deposition in nematodes in the group treated with F. prausnitzii CCFM1204 was significantly lower than that in the control group (P < 0.01).

[0140] In summary, the Clostridium prausnitzii CCFM1204 in the present invention has the effects of prolonging life, anti-oxidation, reducing fat, and reducing lipofuscin deposition, and can be used to prepare drugs for prolonging life, anti-oxidation, reducing fat, and reducing lipofuscin deposition. Those skilled in the art can refer to the content of this article, and appropriately improving the process parameters is within the scope of protection of the present invention.

[0141] It is particularly important to point out that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in the present invention. The products of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the products described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

Claims

1. Use of Faecalibacterium prausnitzii CCFM1204 or its microbial agent in the preparation of a product for prolonging life.

2. The use according to claim 1, It is characterized in that The microbial agent uses Clostridium prausnitzii CCFM1204 as the main microorganism; The number of viable bacteria of Clostridium prausnitzii CCFM1204 in the bacterial agent is not less than 1×10 8 CFU / mL or 1×10 8 CFU / g; the bacterial agent contains living cells of CCFM1204 strain, dry bacteria of CCFM1204 strain obtained by freeze-drying, immobilized cells of CCFM1204 strain, liquid bacterial agent of CCFM1204 strain, solid bacterial agent of CCFM1204 strain, or CCFM1204 strain in any other form.

3. The use according to claim 1, It is characterized in that The bacterial agent may also contain other applicable strains of any genus, including but not limited to Bacillus licheniformis, Saccharomyces cerevisiae, Bacillus subtilis, and Lactobacillus.

4. The use according to claim 1, It is characterized in that The products include but are not limited to medicines, foods, food additives, feeds, feed additives, cosmetics, and health products.

5. The use according to claim 4, It is characterized in that The drug contains Faecalibacterium prausnitzii CCFM1204 or its microbial agent, and pharmaceutically acceptable excipients; Preferably, the dosage form of the drug includes any one of suspension, granules, capsules, powders, tablets, emulsions, solutions, pills, injections, suppositories, enemas, aerosols, patches or drops; Preferably, the administration route of the drug includes oral administration, sublingual administration, skin mucosal administration, inhalation administration or injection; Preferably, the medicine also contains any strain of any genus that can be used in medicine, including but not limited to Bacillus licheniformis, Saccharomyces cerevisiae, Bacillus subtilis, and Lactobacillus.

6. The use according to claim 4, It is characterized in that The food is solid food, liquid food or semi-solid food.

7. The use according to claims 1 to 6, It is characterized in that The number of cells of Clostridium prausnitzii CCFM1204 in the product is not less than 1×10 8 CFU / g or 1×10 8 CFU / mL.

8. Use of Faecalibacterium prausnitzii CCFM1204 or its microbial agent in the preparation of products having the effects of extending lifespan, anti-oxidation, reducing fat and reducing lipofuscin deposition.

9. The use according to claim 8, It is characterized in that The products include but are not limited to drugs, foods, food additives, feeds, feed additives, cosmetics, and health products; the number of cells of Clostridium prausnitzii CCFM1204 in the products is not less than 1×10 8 CFU / g or 1×10 8 CFU / mL.

10. The use according to claim 9, It is characterized in that The medicine contains Clostridium prausnitzii CCFM1204 or its microbial agent, and pharmaceutically acceptable excipients; the food is solid food, liquid food or semi-solid food.